Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA

Jan 30, 2023

Read More

SEC Declares That There Are Currently No Issuers at Risk of Delisting Due to the Holding Foreign Companies Accountable Act

Jan 20, 2023

Read More

Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List

Jan 18, 2023

Read More

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

Jan 09, 2023

Read More

Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Jan 05, 2023

Read More

Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Jan 03, 2023

Read More